350 related articles for article (PubMed ID: 11700390)
21. [Angiogenesis and hematologic malignancy].
Zini JM; Tobelem G
Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis in acute and chronic leukemias.
Dickson DJ; Shami PJ
Leuk Lymphoma; 2001; 42(5):847-53. PubMed ID: 11697639
[TBL] [Abstract][Full Text] [Related]
23. The role of vascular endothelial growth factor in angiogenesis.
Ferrara N; Gerber HP
Acta Haematol; 2001; 106(4):148-56. PubMed ID: 11815711
[TBL] [Abstract][Full Text] [Related]
24. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor as a target opportunity in hematological malignancies.
Bellamy WT
Curr Opin Oncol; 2002 Nov; 14(6):649-56. PubMed ID: 12409656
[TBL] [Abstract][Full Text] [Related]
26. Functions of the VEGF/VEGF receptor system in the vascular system.
Breier G
Semin Thromb Hemost; 2000; 26(5):553-9. PubMed ID: 11129412
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
Sledge GW
Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
[TBL] [Abstract][Full Text] [Related]
28. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
Zhu Z; Witte L
Invest New Drugs; 1999; 17(3):195-212. PubMed ID: 10665474
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
31. SU6668, a multitargeted angiogenesis inhibitor.
Hoekman K
Cancer J; 2001; 7 Suppl 3():S134-8. PubMed ID: 11779084
[TBL] [Abstract][Full Text] [Related]
32. Angiogenesis in hematologic malignancies.
Mesters RM
Ann Hematol; 2002; 81 Suppl 2():S72-4. PubMed ID: 12611085
[No Abstract] [Full Text] [Related]
33. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors of the vascular endothelial growth factor receptor.
Rosen LS
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1173-87. PubMed ID: 12512388
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor and its receptors in multiple myeloma.
Ria R; Roccaro AM; Merchionne F; Vacca A; Dammacco F; Ribatti D
Leukemia; 2003 Oct; 17(10):1961-6. PubMed ID: 14513045
[TBL] [Abstract][Full Text] [Related]
36. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
37. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
38. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
[TBL] [Abstract][Full Text] [Related]
39. Endothelial survival factors as targets for antineoplastic therapy.
Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM
Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081
[TBL] [Abstract][Full Text] [Related]
40. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
